250
Participants
Start Date
May 22, 2024
Primary Completion Date
August 31, 2027
Study Completion Date
February 29, 2028
BBO-8520
Participants will receive assigned dose of BBO-8520 orally (PO), QD
Pembrolizumab
Patients will receive IV pembrolizumab
RECRUITING
Kinghorn Cancer Centre, Darlinghurst
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Peninsula & South Eastern Hematology and Oncology Group (PAS), Frankston
RECRUITING
The Queen Elizabeth Hospital, Woodville South
RECRUITING
Flinders Medical Centre, Bedford Park
RECRUITING
Perlmutter Cancer Center - NYU Langone Health, New York
RECRUITING
NEXT Oncology, Fairfax
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
University of Kansas Medical Center, Kansas City
RECRUITING
Huntsman Cancer Institute, Salt Lake City
RECRUITING
UCLA Health - Santa Monica Cancer Care, Santa Monica
RECRUITING
University of California - San Diego Moores Cancer Center, La Jolla
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Yale Cancer Center, New Haven
RECRUITING
Norwalk Hospital, Norwalk
RECRUITING
Juravinski Cancer Centre, Hamilton
RECRUITING
The Princess Margaret Cancer Centre, Toronto
RECRUITING
Jewish General Hospital, Montreal
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
INDUSTRY